A few months after SK Life Science began rolling out a road trip-themed TV commercial for its antiseizure medication Xcopri, the FDA is attempting to put the brakes on the ad. More: SK Life Science Xcopri ad meets a roadblock
read moreNovo Nordisk has come up short in two phase 3 trials of semaglutide as a treatment for Alzheimer’s disease. But perhaps the larger story associated with the unsurprising result is the market reaction, as Novo’s shares fell by nearly 9%
read moreA combination of Merck-partnered sac-TMT and Keytruda led to a “statistically significant and clinically meaningful” improvement in progression-free survival versus Keytruda alone in a phase 3 trial in first-line PD-L1-positive NSCLC, Kelun said Monday. More: Merck's partner Kelun touts phase
read moreEli Lilly’s latest high-profile crossovers—which include a starry TV partnership and the far-reaching rollout of a new campaign—both tie into the drugmaker’s work to draw more attention to Alzheimer’s disease. More: Lilly levels up Alzheimer’s awareness with Chris Hemsworth collab,
read moreHundreds of industry leaders have signed a letter to FDA Director Marty Makary, M.D., about the importance of having a predictable regulatory agency, citing a survey in which 82% of biopharma respondents said they were concerned about the FDA’s ability
read moreMaryland is becoming the home away from home for British drugmaker AstraZeneca. On Friday, the biopharma powerhouse upped its ante in the Old Line State, saying it will invest $2 billion to increase its manufacturing presence there. More: AstraZeneca boosts
read more© 1994 - 2026 B.M. Pharmaceuticals